TOTOWA, N.J., May 20, 2013 /PRNewswire/ -- BiologicTx® [www.biologictx.com], the first solely focused infusion and pharmacy provider of biologic and oral transplant therapy management, today announced the unveiling of their new proprietary transplant therapeutic data management and analytics program, BiologicTx Sequence™. BiologicTx Sequence is a proprietary data management system that combines a patient's drug therapy interventions with patient specific data to provide the clinician with a global picture of the therapeutic impact and efficacy of the treatment prescribed. BiologicTx Sequence aggregates into a unified database all physician, laboratory, pharmacy and nursing data into one, easy to use and manage database that optimizes patient care.
BiologicTx Sequence was demonstrated at the American Transplant Congress' (ATC) Annual Meeting in Seattle, Washington, from Saturday, May 18th through Tuesday, May 21st, 2013.
"BiologicTx Sequence has the unique ability to aggregate detailed clinical data on the therapeutics administered to BiologicTx® patients exclusively for our prescribing transplant center clinicians. Previously, this information was difficult to provide in a unified and consistent manner. By utilizing BiologicTx Sequence, transplant center clinicians now have the ability to monitor patient responses to individual treatments and assess the efficacy of the course of treatment prescribed by the center as a whole," said Darrin Carrico, President at BiologicTx®.
Sal Rafanelli, RPh and CEO of BiologicTx®, stated, "BiologicTx Sequence will aid in the advancement of progressive and routine biologic and oral transplant therapies. Ultimately, we believe that the use of BiologicTx Sequence, combined with BiologicTx's services, will play a meaningful role in achieving higher success rates in organ transplantation and longer graph survival."
BiologicTx Sequence™: Forward Thinking Technology
BiologicTx Sequence is a HIPAA compliant data management and analytic program that combines data from drug therapy interventions administered by BiologicTx® with transplant center tissue typing, DSA information, and patient specific data. The results of this data provides the transplant center clinicians with a global picture of the therapeutic impact and efficacy of the treatment prescribed along with lab data, graphs, and stratification, used in connection with the treatment of a clinician's patients.
In addition to individual patient information, the clinician will be able to view and evaluate responses to various therapies for all organ types with desensitization, AMR, infection and immunosuppression provided by BiologicTx®. This improved data will help clinician's overcome current challenges in data collection, aggregating lab results, and interpretation of patient's overall clinical progress, which will impact living and deceased donation outcomes.
In addition to BiologicTx Sequence, BiologicTx® has developed BiologicTx Paired Exchange™, a regional living kidney donation network for individuals with end stage renal disease that are difficult to match due to being sensitized.
BiologicTx® is the first, solely focused infusion and pharmacy provider of biologic and oral transplant therapy management. Our team is comprised of dedicated professionals that strive to advance desensitization, immunosuppressive, and rejection treatments, worldwide, resulting in progressive and favorable patient outcomes. We deliver efficient, start to finish services that establish therapeutic services in the home and clinic, acting in concert with the transplant center medical team. This process provides a consistent stream of information and clinical services. In doing so, we provide hope and a better quality of life to our patients. For more information, visit www.biologictx.com.